Defining Early Stages of Polyomavirus CNS Pathogenesis and Immunity

定义多瘤病毒中枢神经系统发病机制和免疫的早期阶段

• 批准号: 10365345
• 负责人: Aron Eliot Lukacher
• 金额: $ 43.09万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10365345
• 关键词: Acquired Immunodeficiency Syndrome; Adult; Animal Model; Anti-Inflammatory Agents; Antibody Repertoire; Antibody Response; Autoimmune; Autoimmunity; B-Lymphocyte Epitopes; Biological; Biological Products; Blood; Brain; Brain Diseases; CD8-Positive T-Lymphocytes; Capsid Proteins; Cells; Central Nervous System Diseases; Central Nervous System Infections; Central Nervous System Viral Diseases; Cerebrum; Choroid Plexus Epithelium; Clinical; Clinical Trials; Complication; Cryoelectron Microscopy; Custom; Demyelinations; Depressed mood; Development; Diagnosis; Disease; Engineering; Ependyma; Epitopes; Event; Family; Foundations; Grant; Hematologic Neoplasms; Human; Immune; Immune Evasion; Immunity; Immunocompromised Host; Immunoglobulin G; Immunologics; Immunomodulators; Immunosuppression; Immunotherapeutic agent; Incidence; Individual; Infection; Inflammatory; Integrin alpha4; JC Virus; Kidney; Lead; Lesion; Life; Link; Maps; Mediating; Modeling; Molecular; Monoclonal Antibodies; Morbidity - disease rate; Mus; Mutant Strains Mice; Mutation; Natural Immunity; Neurotropism; Parents; Pathogenesis; Patients; Plasma Exchange; Polyomavirus; Polyomavirus Infections; Population; Process; Progressive Multifocal Leukoencephalopathy; Reaction; Relapse; Reporting; Resistance; Resolution; Risk; STAT1 gene; Series; Site; Staging; Stretching; Systemic Lupus Erythematosus; T-Lymphocyte; Testing; Therapeutic; Three-Dimensional Imaging; Tropism; Tysabri; Urinary tract; Urine; Validation; Variant; Ventricular; Viral; Viral Pathogenesis; Viremia; Virus; Virus Diseases; brain parenchyma; chemotherapeutic agent; clinical practice; drug candidate; drug withdrawal; human pathogen; human virome; image reconstruction; improved; in vivo; in vivo evaluation; macroglia; mortality; mouse polyomavirus; multiple sclerosis patient; mutant; natalizumab; neuropathology; neutralizing antibody; next generation sequencing; pathogen; pre-clinical; preservation; response; small molecule; subventricular zone; tissue culture

ABSTRACT JC polyomavirus (JCPyV), a ubiquitous human pathogen, causes several devastating brain diseases in immune compromised individuals. The most notable of these JCPyV-associated CNS diseases is the frequently fatal demyelinating brain disease progressive multifocal leukoencephalopathy (PML). PML, an AIDS-defining lesion in the pre-cART epoch, has emerged as a life-threatening complication in patients receiving immunomodulatory agents for autoimmune and inflammatory disorders and treatment for certain hematological malignancies. Among the rapidly expanding list of PML-associated biologics, natalizumab (Tysabri®) has the highest incidence and is an ominous sequela for multiple sclerosis (MS) patients who otherwise benefit from dramatic reductions in relapses using this immunomodulatory agent. Drug withdrawal, the only therapeutic option for PML, is often complicated by a high-mortality cerebral inflammatory reaction. No anti-JCPyV agents are available. Lack of a tractable animal model of polyomavirus-induced CNS disease is an acknowledged bottleneck to elucidating PML pathogenesis, timmunological mechanisms that control JCPyV, in vivo evaluation of agents that inhibit polyomavirus replication in tissue culture, and uncovering early events that presage irreversible JCPyV-associated neuropathology – the focus of this renewal application. Using mouse polyomavirus (MuPyV), we developed a natural virus-host model of polyomavirus-associated CNS disease. In this renewal application, we will leverage two key findings made under the parent R01 grant: (1) Mapping JCPyV-PML VP1 capsid protein mutations to MuPyV’s VP1 confers escape from virus-neutralizing antibodies (nAb) while preserving CNS tropism; and (2) STAT1-dependent innate immunity limits infection of the ventricular ependyma, a critical barrier to subsequent brain parenchymal infection. Both findings, which parallel those of JCPyV, lay the foundation for the two key questions raised in this renewal application: (1) Is the ependyma the staging ground for polyomavirus invasion of the brain parenchyma?; and (2) Does T cell deficiency open the door for outgrowth of nAb-escape virus variants? The proposed studies will make use of cutting edge advances in next-generation sequencing to uncover rare VP1 mutations in vivo, custom cryo EM image reconstruction approaches to define endogenous VP1 nAb epitopes and nAb escape mechanisms, and high-resolution 3D imaging of mouse brains to visualize viral CNS entry and spread. Findings from these studies will answer fundamental questions about innate and adaptive immune control of JCPyV and potentially improve criteria for identifying patients at risk for JCPyV-associated CNS diseases.

摘要 JC多瘤病毒（JCPyV）是一种普遍存在的人类病原体，在人类中引起几种毁灭性的脑部疾病。 免疫力低下的人。这些JCPyV相关CNS疾病中最值得注意的是 经常是致命的脱髓鞘性脑疾病进行性多灶性白质脑病（PML）。PML，一种 cART前阶段的艾滋病定义性病变已成为患者危及生命的并发症 接受用于自身免疫性和炎性疾病的免疫调节剂以及用于某些 血液恶性肿瘤在迅速扩大的PML相关生物制剂清单中，那他珠单抗 （Tysabri®）的发病率最高，是多发性硬化症（MS）患者的不祥后遗症， 否则受益于使用该免疫调节剂显著减少复发。停药， 作为PML的唯一治疗选择，常并发高死亡率的脑炎症反应。没有 抗JCPyV剂是可用的。缺乏易处理的多瘤病毒诱导的CNS疾病的动物模型， 阐明PML发病机制的公认瓶颈，控制JCPyV的免疫学机制， 在组织培养物中抑制多瘤病毒复制的试剂的体内评价，以及揭示 预示着不可逆的JCPyV相关神经病理学-这一更新申请的重点。使用小鼠 为了研究多瘤病毒（MuPyV），我们开发了多瘤病毒相关CNS疾病的天然病毒宿主模型。在 在这一更新申请中，我们将利用在母R 01补助金下取得的两项关键发现：（1）绘制 JCPyV-PML VP 1衣壳蛋白突变为MuPyV的VP 1，可逃避病毒中和抗体 (nAb)同时保持CNS向性;和（2）STAT 1依赖性先天免疫限制了 脑室室管膜是随后脑实质感染的关键屏障。这两项发现， （1）在本更新申请中提出的两个关键问题奠定了基础：（1） 室管膜是多瘤病毒侵入脑实质的舞台？（2）T细胞 缺乏为nAb逃逸病毒变体的生长打开了大门？拟议的研究将利用 下一代测序的前沿进展，以揭示体内罕见的VP 1突变，定制冷冻EM 确定内源性VP 1 nAb表位和nAb逃逸机制的图像重建方法，以及 小鼠大脑的高分辨率3D成像，以可视化病毒CNS进入和扩散。这些调查结果 研究将回答有关JCPyV的先天和适应性免疫控制的基本问题， 用于鉴别具有JCPyV相关CNS疾病风险患者的改进标准。